[Ip-health] Inside US Trade: Brand-Name Drug Companies Want Clarity On U.S. IPR Proposal In TPP

Jamie Love james.love at keionline.org
Fri Oct 7 08:24:38 PDT 2011

On Fri, Oct 7, 2011 at 10:33 AM, Michael Palmedo
<mpalmedo at wcl.american.edu>wrote:

> [snip]
> Drug companies would prefer to receive stronger patent protections in

   "Stronger patent protections"?    What is this supposed to mean?  That
the WTO obligations are not strong enough for Peru, Chile,
Thailand, Malaysia and Vietnam?

Also, while the pharmaceutical industry foreign governments are briefed by
USTR, the White House insists that the public is kept in the dark.

> all TPP countries after quickly applying for approval in just one of the
> TPP countries. One industry source said USTR has referred to only one
> single "window" of time and would likely not require companies to seek
> approval in nine countries to enjoy stronger protections.
> [snip]
> http://insidetrade.com/Inside-US-Trade/Inside-U.S.-Trade-10/07/2011/bran
> d-name-drug-companies-want-clarity-on-us-ipr-proposal-in-tpp/menu-id-172
> .html
> Brand-Name Drug Companies Want Clarity On U.S. IPR Proposal In TPP
> Posted: October 6, 2011
> Representatives of the U.S. brand-name drug industry this week said they
> are still unclear on exactly how the U.S. proposal on patent protections
> in the Trans-Pacific Partnership (TPP) talks would work, especially when

More information about the Ip-health mailing list